Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127175 | 0.80 | TSHR (0.39) | MAOAMAOBCYP3A4CYP2C19TSHR | |
| SCHEMBL20025577 | 0.76 | MAOA (0.44) | MAOAMAOBTSHRACHEHPGD | |
| SCHEMBL26936333 | 0.75 | ACHE (0.43) | MAOAMAOBCYP3A4CYP2C19TSHR | |
| SCHEMBL4441911 | 0.74 | CYP3A4 (0.56) | MAOAMAOBCYP3A4CYP2C19TSHR | |
| SCHEMBL12894063 | 0.74 | SMN1; SMN2 (0.36) | MAOAMAOBCYP3A4CYP2C19TSHR | |
| SCHEMBL27374178 | 0.74 | ERCC5 (0.41) | CYP3A4CYP2C19TSHRHPGDERCC5 | |
| SCHEMBL8219584 | 0.72 | NR4A1 (0.50) | CYP3A4TSHRHPGDCYP2D6NPC1 | |
| SCHEMBL22343688 | 0.72 | MAOA (0.42) | MAOAMAOBTSHRACHEHPGD | |
| SCHEMBL6051363 | 0.72 | TSHR (0.45) | MAOAMAOBCYP3A4CYP2C19TSHR | |
| SCHEMBL14141082 | 0.71 | POLB (0.39) | MAOAMAOBCYP3A4CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | MAOA 4262/4885MAOB 4177/4885CYP3A4 3918/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | MAOA 4262/4885MAOB 4177/4885CYP3A4 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.